MedTrace Logo

Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)

NCT01284608 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 197

Last updated 2012-12-24

No results posted yet for this study

Summary

This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten years using FRAX model in patients with prostate cancer. The patients will be following for 12 months

Conditions

  • Prostatic Cancer

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01284608 on ClinicalTrials.gov